LEUKEMIA & LYMPHOMA

Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study

Time from first symptom onset to the final diagnosis of multiple myeloma (MM) – possible risks and future solutions: retrospective and prospective ‘Deutsche Studiengruppe MM’ (DSMM) and ‘European Myeloma Network’ (EMN) analysis*

Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies

Asparaginase activity monitoring experience from the Maritimes, Canada

Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis

Myosteatosis in adolescents and young adults treated for acute lymphoblastic leukemia

Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment

Real world experience with “generic” pomalidomide in relapsed refractory multiple myeloma

Posterior reversible encephalopathy syndrome in pediatric patients: pathophysiology, diagnosis, and management

Improved survival rates of AML patients following admission to the intensive care unit

A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†

1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib

Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia*

High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia – lessons for immunopathogenesis and prescribing

Prognostic factors and nomogram for survival prediction in patients with primary pulmonary lymphoma: a SEER population-based study

MMP-10 and TIMP-1 as indicators of severe sepsis in adult hematological patients with febrile neutropenia

Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected

Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study

Second-generation immunomodulatory drugs in leptomeningeal myeloma

Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid

Checkpoint inhibitor-induced autoimmune encephalitis reversed by rituximab after allogeneic bone marrow transplant in a patient with Hodgkin lymphoma

PALB2 variant status in hematological malignancies – a potential therapeutic target?

Human herpes virus 6 reactivation following autologous hematopoietic cell transplantation – a single-center experience

Successful treatment with mogamulizumab of refractory/relapsed angioimmunoblastic T-cell lymphoma following autologous stem cell transplantation

The effect of melphalan dose and total body irradiation as reduced-intensity conditioning for acute lymphoblastic leukemia patients undergoing allogeneic stem cell transplantation

A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells

FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia

Improvement of thyroid function in POEMS syndrome after combination therapy of lenalidomide and dexamethasone

Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease

New murine models of aggressive lymphoma

Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center

Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status

Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET)

Mutations and prognosis in myeloproliferative neoplasms

What a headache! Double-hit lymphoma with CNS recurrence – Role of chimeric antigen receptor (CAR) T-cell therapy

Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma

A diffuse large B cell lymphoma with clinical, imaging, and serologic characteristics of neuromyelitis optica spectrum disorder

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis

Anti-leukemia effect of vitamin K3 is mediated through mitochondrial complexes I and II

Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis

Detection of hemophagocytic extremely multinucleated giant plasma cells after rituximab/low-dose lenalidomide treatment in CD20+ multiple myeloma

Concerning survival signal for eltrombopag in MDS/AML

Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution

Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response

Suppression of minichromosome maintenance 7 expression sensitizes chronic lymphocytic leukemia cells to fludarabine

No differential overall or relative survival effect of rituximab in male and female patients with diffuse large B-cell lymphoma: a Danish population-based study of 3783 patients